{"id":24369,"date":"2019-02-12T12:00:00","date_gmt":"2019-02-12T12:00:00","guid":{"rendered":"https:\/\/www.euforea.org\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/"},"modified":"2019-02-12T12:00:00","modified_gmt":"2019-02-12T12:00:00","slug":"conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma","status":"publish","type":"news","link":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/","title":{"rendered":"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma"},"content":{"rendered":"<div class=\"paragraph paragraph--text-columns paragraph-id--1481 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<h2>Rhinology Future Debates Brussel 2018<\/h2>\n<p>In deze korte video deelt prof. dr. Claus Bachert zijn visie op therapie en monoklonale antilichamen.<\/p>\n<h3>Panelleden<\/h3>\n<p>Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, pati\u00ebntenvertegenwoordigers.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"paragraph paragraph--text-columns paragraph-id--1482 paragraph--type--text-columns paragraph--view-mode--default clearfix paragraph--text-columns--1col\">\n<div class=\"inner--wide\">\n<div class=\"text__text text text--paragraph\">\n<div class=\"video-container\"><center><iframe title=\"YouTube-videospeler\" src=\"https:\/\/www.youtube.com\/embed\/ItSpdFhs_cA?rel=0\" width=\"560\" height=\"315\" frameborder=\"0\" allowfullscreen=\"allowfullscreen\"><\/iframe><\/center><\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Rhinology Future Debates Brussel 2018 In deze korte video deelt prof. dr. Claus Bachert zijn visie op therapie en monoklonale antilichamen. Panelleden Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, pati\u00ebntenvertegenwoordigers.<\/p>\n","protected":false},"author":1,"featured_media":24379,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"categories":[233],"tags":[150,152,154,181,200,223,234,235,236],"class_list":["post-24369","news","type-news","status-publish","has-post-thumbnail","hentry","category-rhinology-future-debates","tag-chronische-rhinosinusitis-crs","tag-crswnp","tag-zorgverleners","tag-biologicals","tag-patienten","tag-astma","tag-rhinologie","tag-debatten","tag-rhinology-future-debates"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.3 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma - EUFOREA<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma\" \/>\n<meta property=\"og:description\" content=\"Rhinology Future Debates Brussel 2018 In deze korte video deelt prof. dr. Claus Bachert zijn visie op therapie en monoklonale antilichamen. Panelleden Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, pati\u00ebntenvertegenwoordigers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/\" \/>\n<meta property=\"og:site_name\" content=\"EUFOREA\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/euforea\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@euforea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/\",\"name\":\"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma - EUFOREA\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"datePublished\":\"2019-02-12T12:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/Rhinology20Future20Debates202018_22.png\",\"width\":1280,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/kies-uw-traject\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#website\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/\",\"name\":\"EUFOREA\",\"description\":\"Inspiring the Future of Respiratory Care\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#organization\",\"name\":\"EUFOREA\",\"url\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"contentUrl\":\"https:\\\/\\\/s3.nl-ams.scw.cloud\\\/euforea-wp-production\\\/uploads\\\/euforea.png\",\"width\":500,\"height\":500,\"caption\":\"EUFOREA\"},\"image\":{\"@id\":\"https:\\\/\\\/www.euforea.org\\\/nl\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/euforea\\\/\",\"https:\\\/\\\/x.com\\\/euforea\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/euforea\",\"https:\\\/\\\/www.youtube.com\\\/c\\\/EUFOREA\",\"https:\\\/\\\/www.instagram.com\\\/euforeaofficial\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma - EUFOREA","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/","og_locale":"nl_NL","og_type":"article","og_title":"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma","og_description":"Rhinology Future Debates Brussel 2018 In deze korte video deelt prof. dr. Claus Bachert zijn visie op therapie en monoklonale antilichamen. Panelleden Catherine Lucet, Claus Bachert, Joaquim Mullol, Peter Hellings, Charles Pilette, Renaud Louis, Philippe Rombaux, pati\u00ebntenvertegenwoordigers.","og_url":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/","og_site_name":"EUFOREA","article_publisher":"https:\/\/www.facebook.com\/euforea\/","twitter_card":"summary_large_image","twitter_site":"@euforea","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/","url":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/","name":"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma - EUFOREA","isPartOf":{"@id":"https:\/\/www.euforea.org\/nl\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/#primaryimage"},"image":{"@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/#primaryimage"},"thumbnailUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","datePublished":"2019-02-12T12:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/#primaryimage","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/Rhinology20Future20Debates202018_22.png","width":1280,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.euforea.org\/nl\/news\/conclusie-over-de-uitdagingen-voor-de-implementatie-van-biologicals-bij-patienten-met-crswnp-en-astma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.euforea.org\/nl\/kies-uw-traject\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/www.euforea.org\/nl\/news\/"},{"@type":"ListItem","position":3,"name":"Conclusie over de uitdagingen voor de implementatie van biologicals bij pati\u00ebnten met CRSwNP en astma"}]},{"@type":"WebSite","@id":"https:\/\/www.euforea.org\/nl\/#website","url":"https:\/\/www.euforea.org\/nl\/","name":"EUFOREA","description":"Inspiring the Future of Respiratory Care","publisher":{"@id":"https:\/\/www.euforea.org\/nl\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.euforea.org\/nl\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.euforea.org\/nl\/#organization","name":"EUFOREA","url":"https:\/\/www.euforea.org\/nl\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.euforea.org\/nl\/#\/schema\/logo\/image\/","url":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","contentUrl":"https:\/\/s3.nl-ams.scw.cloud\/euforea-wp-production\/uploads\/euforea.png","width":500,"height":500,"caption":"EUFOREA"},"image":{"@id":"https:\/\/www.euforea.org\/nl\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/euforea\/","https:\/\/x.com\/euforea","https:\/\/www.linkedin.com\/company\/euforea","https:\/\/www.youtube.com\/c\/EUFOREA","https:\/\/www.instagram.com\/euforeaofficial\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/24369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/comments?post=24369"}],"version-history":[{"count":0,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/news\/24369\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media\/24379"}],"wp:attachment":[{"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/media?parent=24369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/categories?post=24369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euforea.org\/nl\/wp-json\/wp\/v2\/tags?post=24369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}